ReviewPharmacological research2026
Sensory decline in aging and neurodegeneration: A mitochondrial perspective.
Review in Pharmacological research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
- Erratum issued
Authors and funding
20 authors.
Funding
Abstract
Sensory organs (touch, sight, hearing, smell, and taste) are the primary way humans perceive the environment. Accordingly, sensory decline deleteriously affects patients' quality of life, and it is often associated with a worse prognosis of related pathologies. This decline has been broadly described in aging and in the main aging-related neurodegenerative disorders, even though it is often understudied and considered a minor symptom. The molecular pathways that drive aging-associated sensory decline are broad and diverse; however, mitochondrial dysfunction has been described at the intersection of many of these mechanisms. Mitochondria have robust mechanisms to maintain their homeostasis. These mechanisms include, for example, the unfolded protein response, the antioxidant systems, and mitophagy. During aging, these mechanisms are dysregulated, which contributes to the dysfunction of the organelle. For example, increased reactive oxygen species generation and mitochondrial DNA mutations are present in cells and tissues, the dysregulation of which is crucial for the onset of sensory decline. In this bibliographical review, we systematically and comprehensively discuss the most significant and recent findings in the field. The studies we describe here suggest that targeting mitochondrial dysfunction could be a valid, innovative, and promising pharmacological target against sensory decline in aging and aging-related neurodegenerative disorders. Moreover, targeting mitochondrial dysfunction might have positive effects on other symptoms of aging and associated pathologies, including Parkinson's and Alzheimer's Diseases. Further research in the field could significantly contribute to decreasing sensory decline, which could positively impact both lifespan and healthspan.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.